The global biobanking market is on track for major expansion over the next decade, according to an SNS Insider outlook released through GlobeNewswire. The report says the sector was valued at USD 89.96 billion in 2025 and is projected to reach USD 206.61 billion by 2035, pointing to sustained growth as demand rises across research and healthcare.
Biobanking plays a central role in collecting, processing and storing biological samples used in scientific studies, drug development and clinical programs. The market outlook highlights growing genomics research and wider precision medicine efforts as key forces supporting demand, as organizations increasingly rely on high-quality sample repositories and related services.
The U.S. is expected to remain a major contributor to industry growth. SNS Insider estimates the U.S. biobanking market will rise from USD 35.71 billion in 2025 to USD 66.92 billion by 2035. Europe is also forecast to post strong gains, expanding from USD 26.99 billion to USD 59.57 billion over the same period.
The latest projections reflect how biobanking is becoming more important to modern healthcare infrastructure and life sciences research. As personalized treatment strategies, large-scale genomic analysis and long-term sample preservation become more common, the sector appears positioned for continued investment and broader adoption worldwide.
